Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Revenue to Attain USD 2.79 Bn by 2033

18 Jun 2025

Share :

Table of Content

1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Insights 4. Regional Insights 5. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Coverage 6. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Key Players

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Revenue and Trends 2025 to 2033

The global alpha-1 antitrypsin deficiency augmentation therapy market revenue reached USD 1.75 billion in 2025 and is predicted to attain around USD 2.79 billion by 2033 with a CAGR of 6.14%. The increased awareness regarding genetic diseases, increasing diagnosis rates, and technological advancements in protein therapies are expected to boost the growth of the market during the forecast period.

Market Overview

The alpha-1 antitrypsin deficiency augmentation therapy market is experiencing significant growth, driven by increased awareness and the global prevalence of alpha-1 antitrypsin deficiency (AATD), a rare genetic condition increasing the risk of lung and liver diseases like emphysema. Improvements in diagnostic techniques are enabling early diagnosis, leading to higher demand for AATD therapy. There is a high demand for personalized medicine, which creates immense opportunities in the market.

Advances in biotechnology and innovations in treatment options open up new growth avenues. Increasing research and development activities focused on rare diseases, along with government funding for R&D, also contribute to the growth of the market. Moreover, regulatory support for orphan drugs, growing aging population, and the rising prevalence of chronic obstructive pulmonary disease (COPD), which often affects individuals with AATD, are expected to boost the growth of the market in the coming years.

Segment Insights

• By product type, the Prolastin C segment dominated the market with the largest revenue share in 2024. This is mainly due to its proven effectiveness in treating AATD and broad FDA approval. Thus, it is widely used in augmentation therapy for AADT-related lung diseases.
• By end-user, the hospitals segment held the largest share of the market in 2024. The availability of advanced diagnostic tools, drug delivery systems, and skilled expertise encourage patient to receive care from these settings, driving patient footfall. The ability of hospitals to provide total care further support segmental growth. Meanwhile, specialty clinics segment is expected to grow at a rapid pace during the projection period. This is mainly due to the rising demand for personalized care plans.

Regional Insights

North America dominated the alpha-1 antitrypsin deficiency augmentation therapy market in 2024. The growth of the market in the region is driven by the increased prevalence of AATD-related respiratory diseases. The region’s advanced healthcare system and increased investments in R&D further support market growth. Meanwhile, Asia Pacific is projected to grow at the fastest rate in the upcoming period. The awareness about AATD-related respiratory and lung diseases is a major factor driving the growth of the market in the region. Moreover, the rising prevalence of genetic and rare diseases and increasing government investments to advance healthcare infrastructure further support regional market growth.

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Coverage

Recent Developments

• In February 2024, Grifols introduced 4- and 5-gram vials of PROLASTIN (alpha1-proteinase inhibitor [human]) used for long-term alpha1 antitrypsin (AAT) augmentation therapy in patients with severe alpha1-antitrypsin deficiency (alpha-1) who show evidence of progressive lung disease.
  (Source- https://www.grifols.com)

Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Key Players

• Takeda Pharmaceutical Company Limited
• CSL Behring
• Paramount Therapeutics
• Vertex Pharmaceuticals Incorporated
• Shire plc
• Chiesi Farmaceutici SpA
• Shanghai RAAS Biotechnology Co.
• JCR Pharmaceuticals Co.
• Instituto Butantan
• Lonza Group Ltd
• Samsung BioLogics
• Boehringer Ingelheim

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6241

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344